Close Menu

Fred Hutchinson Cancer Research Center

Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.

The company combines screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.

Muneesh Tewari, a former Fred Hutchinson Cancer Research Center scientist who recently moved to the University of Mic